CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas

Pascual-García, Mónica; Bértolo, Cristina; Nieto, Juan C.; Serrat, Neus; Espinosa, Íñigo; D’Angelo, Emanuela; Muñoz, Raquel; Rovira, Ramón; Vidal, Sílvia; Prat, Jaime

doi:10.1016/j.humpath.2016.05.025

Cited by 19 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, there was a lower number of CD8 + T cells in the peripheral blood from patients with endometrioid grade 3 EC, who had not received radio-or chemotherapy before surgery, compared with that in the healthy group. Additionally, these data also indicated that CD8 expression was downregulated in EC (24). In another study involving 90 patients with EC, Kondratiev et al (25) demonstrated that an increase in the number of CD8 + T cells at the invasive border of the tumor epithelium is a favorable prognostic factor for patients with EC.…”

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 90%

“…Pascual-García et al ( 24 ) analyzed 35 neoplastic and 23 non-neoplastic endometrial samples, as well as corresponding peripheral blood samples, and demonstrated that the number of CD8 + T cells was lower in the endometrium of patients with EC than in the endometrium of control subjects. Furthermore, there was a lower number of CD8 + T cells in the peripheral blood from patients with endometrioid grade 3 EC, who had not received radio- or chemotherapy before surgery, compared with that in the healthy group.…”

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 99%

See 1 more Smart Citation

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

et al. 2020

View full text Add to dashboard Cite

Immunotherapy is an emerging clinical approach that has gained traction over the past decade as a novel treatment option for lung cancer and melanoma. Notably, researchers have made marked improvements in the treatment of endometrial cancer (EC), and potential immune responses have been identified in patients with EC, thereby offering the possibility of exploring immunotherapy for EC. Nevertheless, various needs remain unmet, and immunotherapy applications in EC have yielded limited success, as only a minority of patients exhibited a clinical response. Therefore, further understanding of immune dysfunction associated with EC is still required. The present review describes recent findings regarding the immunosuppressive microenvironment of EC, with emphasis on immune evasion mechanisms and immunotherapy in EC.

show abstract

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 90%

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 99%

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Pascual-Garcia et al showed that despite a rise in the number of cytotoxic lymphocytes (CTLs) in endometrial cancer (particularly those of high grade), the CD8 expression on these CTLs is downregulated to reduce their responsiveness. This results in a greater antigen presentation requirement to activate the CTLs and was reflected in both tumour stroma and peripheral blood [61]. Elevated levels of CD4þ CD25þ regulatory T cells are related to a poor prognosis in endometrial cancer [62] and indicate active immune response to carcinogenesis within the endometrium.…”

Section: Tissue Basedmentioning

confidence: 99%

The role of biomarkers in endometrial cancer and hyperplasia: a literature review

et al. 2019

View full text Add to dashboard Cite

Introduction: Endometrial cancer is the most common gynaecological cancer and its incidence is rising due to increasing obesity rates. We are also seeing an increasing trend of young women diagnosed with either endometrial cancer or its precancerous state, endometrial hyperplasia. Diagnosis is dependent on invasive testing and there is no screening tool available for either general or high-risk population groups.Whilst vast amounts of research have been undertaken in higher-profile cancers such as ovarian and cervical, endometrial cancer is comparatively less investigated. Aim: In this literature review, we summarise the existing literature in understanding the role of tumour biomarkers for endometrial cancer and its preceding condition of endometrial hyperplasia. Method: NICE Healthcare Databases Search tool was used to search Embase, Medline and PubMed databases for relevant articles. Conclusion: There is currently no routinely used biomarker in endometrial cancer for diagnostic or prognostic purposes. Given the establishment of new genomic classifications of endometrial cancers, the use of biomarkers to drive therapeutic approaches will be the cornerstone for individualised cancer care in the coming decades. ARTICLE HISTORY

show abstract

“…Interestingly, these tumors have been reported to have a better prognosis than common invasive breast carcinoma subsequently firstly to a better response to chemotherapy due to intense mitotic activity and secondly the increase of T-lymphocytes and particularly CD8 cytotoxic T-lymphocytes which play a crucial function in antitumor response [25]. Classically, in high grade endometrioid and serous carcinoma of the endometrium often associated with p53 mutations and a poor clinical outcome, there is a major CD8 downregulation on cytotoxic T-lymphocytes [28]. Therefore, the alterations on cell cycle, apoptosis, and/or senescence consecutive to the loss p53 function by mutations are not counterbalanced by antitumoral immune response.…”

Section: Discussionmentioning

confidence: 99%

PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium

Bienfait

D’Haene

Catteau

et al. 2018

Case Reports in Pathology

View full text Add to dashboard Cite

Lymphoepithelioma-like carcinoma of the endometrium is a very rare variant of endometrial carcinoma characterized by syncytial nests of pleomorphic epithelial cells and heavy infiltration of the stroma by lymphocytes (in particular CD8 cytotoxic T-lymphocytes) and plasma cells. Until now, only five cases have been characterized in this location. This report describes the clinicopathological and the molecular features of this unusual tumor. In particular, using the next generation sequencing (NGS) technique, we have demonstrated that this tumor could be associated with PIK3CA and p53 gene mutations. These data have not been reported to date and suggest that lymphoepithelioma-like carcinoma of the endometrium shares common molecular features with high grade endometrioid and serous-like endometrial carcinoma which are associated with poor outcome. Nevertheless, in endometrial lymphoepithelioma-like carcinoma, the alterations on cell cycle, apoptosis, and/or senescence secondary to p53 mutations could potentially be counterbalanced by the antitumoral response induced by CD8 cytotoxic T-lymphocytes numerous in these tumors.

show abstract

CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas

Cited by 19 publications

References 27 publications

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

The role of biomarkers in endometrial cancer and hyperplasia: a literature review

PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium

Contact Info

Product

Resources

About